NAD advises Synaptol to change advertising

March 25th, 2013

The NAD, the investigative unit of the advertising industry’s system of self-regulation, is advising Hello Life, LLC, to halt advertising Synaptol as a treatment for ADD and ADHD:

The National Advertising Division has recommended that Hello Life, LLC, discontinue unsupported claims that its Synaptol, a homeopathic remedy, treats or relieves symptoms of Attention Deficit Disorder or Attention Deficit/Hyperactivity Disorder (ADD/ADHD).

NAD further recommended that the advertiser discontinue its use of testimonials claiming that Synaptol treats ADD/ADHD symptoms or that is can be used as a replacement for or alternative to prescription treatments for ADD/ADHD.

Hello Life responded to the NAD, and voluntarily pulled a number of their claims about Synaptol, though not all. Read the full press release here.

Print Friendly, PDF & Email

The National Advertising Division, or NAD, is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus. NAD asks advertisers to substantiate or change their claims in advertisements. As part of a voluntary system of self-regulation, however, its recommendations can be ignored by the offending advertisers. In those instances, NAD refers the offender to federal consumer protection agencies.

Leave a Reply

Back to Top ↑